cb
recent
identifi
drug
target
sever
form
cancer
current
potent
select
cb
inhibitor
avail
use
composit
collect
clinic
use
drug
wellannot
pharmacolog
compound
includ
lopac
librari
fda
approv
drug
librari
nih
clinic
collect
new
prestwick
chemic
librari
us
drug
collect
intern
drug
collect
killer
plate
collect
small
custom
collect
plpdepend
enzym
inhibitor
conduct
vitro
screen
order
identifi
inhibitor
cb
use
primari
azmc
screen
detect
cbsderiv
hydrogen
sulfid
h
product
initi
hit
subject
counterscreen
use
methylen
blue
assay
secondari
assay
measur
h
product
assess
abil
quench
h
signal
produc
h
donor
compound
four
compound
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
show
concentrationdepend
cb
inhibitori
action
without
scaveng
h
releas
identifi
direct
cb
inhibitor
hexachlorophen
ic
tannic
acid
ic
benserazid
ic
less
potent
cb
inhibitor
two
refer
compound
aoaa
ic
ic
aurintricarboxyl
acid
ic
equipot
aoaa
second
refer
compound
inhibit
cbsinduc
azmc
fluoresc
signal
ic
also
inhibit
azmc
fluoresc
signal
ic
indic
scavengingnonspecif
effect
hexachlorophen
ic
tannic
acid
ic
benserazid
ic
ic
inhibit
colon
cancer
cell
prolifer
greater
potenc
aoaa
ic
contrast
although
cb
inhibitor
cellfre
assay
aurintricarboxyl
acid
fail
inhibit
prolifer
lower
concentr
stimul
cell
prolifer
coppercontain
compound
present
librari
also
found
potent
inhibitor
recombin
cb
howev
activ
due
cb
inhibitori
effect
copper
ion
howev
copper
ion
inhibit
cell
prolifer
benserazid
weak
inhibitor
activ
h
sgener
enzym
cse
activ
inhibit
respect
vitro
benserazid
suppress
mitochondri
function
inhibit
prolifer
high
cbsexpress
colon
cancer
cell
line
low
cbsexpress
line
lovo
major
benserazid
metabolit
also
inhibit
cb
activ
suppress
cell
prolifer
vitro
vivo
studi
nude
mice
bear
human
colon
cancer
cell
xenograft
benserazid
mgkgday
sq
prevent
tumor
growth
silico
dock
simul
show
benserazid
bind
activ
site
enzym
react
plp
cofactor
form
revers
kinet
stabl
schiff
baselik
adduct
formyl
moieti
pyridox
conclud
benserazid
inhibit
cb
activ
suppress
colon
cancer
cell
prolifer
bioenerget
vitro
tumor
growth
vivo
pharmacokinet
pharmacodynam
preclin
anim
studi
necessari
evalu
potenti
repurpos
benserazid
treatment
colorect
cancer
part
pioneer
work
led
descript
character
transsulfur
pathway
du
vigneaud
note
product
hydrogen
sulfid
h
liver
homogen
incub
homocystein
know
enzym
respons
effect
cb
pyridox
plp
depend
enzym
express
variou
cell
liver
kidney
nervou
system
play
role
cystein
biosynthesi
degrad
cb
uniqu
among
plpdepend
enzym
also
carri
ntermin
heme
prosthet
group
coordin
residu
although
heme
requir
enzymat
activ
presenc
affect
catalyt
activ
serv
redox
sensor
ctermin
region
cb
exert
autoinhibitori
function
partial
shield
activ
site
allevi
sadenosyl
methionin
bind
h
product
cbsmediat
cystein
degrad
well
sever
mammalian
enzym
well
recogn
signal
molecul
mammal
control
fundament
cellular
process
includ
growth
differenti
movement
cell
death
molecular
level
h
regul
process
alter
activ
protein
kinas
membran
ion
channel
nuclear
transcript
factor
well
key
mitochondri
protein
involv
regul
cellular
bioenerget
recent
discov
cb
abundantli
overexpress
colon
cancer
compar
surround
normal
colon
mucosa
cb
overexpress
also
detect
multipl
colon
cancer
cell
line
includ
lovo
rel
overexpress
cb
also
report
ovarian
breast
bladder
cancer
review
pharmacolog
inhibit
knockdown
cb
inhibit
prolifer
cancer
cell
line
reduc
growth
tumor
xenograft
vivo
identifi
cb
preclinicallyvalid
anticanc
drug
target
cb
also
propos
therapeut
target
nonalcohol
fatti
liver
diseas
stroke
howev
current
potent
select
cb
inhibitor
avail
aminooxyacet
acid
aoaa
commonli
refer
select
cb
inhibitor
even
though
also
inhibit
anoth
h
sproduc
enzym
cystathioninegamma
lyas
cse
well
sever
transaminas
previou
effort
identifi
cb
inhibitor
commerci
avail
librari
yield
compound
rel
low
potenc
limit
cb
select
instanc
recent
highthroughput
tandemmicrowel
assay
identifi
e
dion
cb
inhibitor
howev
also
inhibit
cse
potenc
lower
effort
identifi
cb
inhibitor
conduct
screen
composit
librari
drug
wellannot
pharmacolog
compound
screen
identifi
sever
cb
inhibitor
includ
benserazid
addit
studi
demonstr
benserazid
effect
inhibitor
colon
cancer
cell
prolifer
vitro
tumor
xenograft
growth
vivo
suggest
potenti
therapeut
repurpos
antitumor
agent
unless
otherwis
specifi
compound
obtain
sigmaaldrich
except
studi
use
librari
use
predissolv
drug
dmso
compound
dissolv
freshli
prior
experi
recombin
full
length
human
cb
purchas
genscript
inc
piscataway
nj
azmc
base
screen
modifi
carri
plate
format
autom
robot
system
standalon
robot
system
compris
plate
washer
biotek
winooski
vt
dispens
microflo
biotek
winooski
vt
pipet
station
precis
biotek
winooski
vt
incub
cytomat
thermo
electron
corpor
ashevil
nc
plate
reader
synergi
biotek
winooski
vt
connect
robot
arm
twister
ii
calip
life
scienc
inc
hopkinton
test
compound
dissolv
dimethyl
sulfoxid
dmso
ad
well
yield
final
concentr
dmso
total
assay
volum
assay
solut
contain
tri
hcl
mm
ph
human
recombin
fulllength
cb
cb
substrat
lcystein
homocystein
mm
final
concentr
pyridox
plp
final
concentr
h
sspecif
fluoresc
probe
azmc
final
concentr
well
plate
incub
increas
azmc
fluoresc
well
read
nm
nm
twohour
time
cours
standard
curv
gener
use
differ
concentr
h
donor
nah
cb
inhibitor
aoaa
dion
also
known
toxoflavin
xanthothricin
use
posit
control
dmso
use
neg
control
data
analyz
export
excel
cb
assay
outlin
modifi
way
instead
recombin
cb
h
donor
final
concentr
mm
ad
assay
mixtur
gener
fluoresc
azmc
signal
compound
inhibit
signal
classifi
nonspecif
inhibitor
either
scaveng
h
interfer
detect
method
methylen
blue
assay
commonli
use
detect
h
modifi
format
test
compound
ad
well
dmso
yield
final
concentr
control
well
receiv
dmso
posit
control
well
receiv
concentr
aoaa
volum
activ
buffer
contain
mm
tri
hcl
ph
human
recombin
fulllength
cb
cb
substrat
lcystein
homocystein
mm
final
concentr
pyridox
plp
final
concentr
plate
seal
pcr
strip
incub
h
incub
plate
put
directli
ice
next
strip
remov
plate
znac
ad
follow
tca
subsequ
mm
n
ndimethylpphenylenediamin
mm
fecl
ad
well
plate
incub
min
room
temperatur
dark
absorb
read
nm
azmc
assay
describ
modifi
assess
effect
benserazid
cystathioninegamma
lyas
cse
sulfurtransferas
activ
recombin
human
cse
obtain
novu
biolog
cse
activ
cse
per
well
incub
substrat
lcystein
mm
tri
hcl
buffer
h
follow
detect
h
via
azmc
method
describ
activ
per
well
incub
substrat
mm
tri
hcl
buffer
h
follow
detect
h
via
azmc
method
describ
monitor
cell
prolifer
real
time
use
xcellig
system
describ
system
measur
electr
imped
across
interdigit
microelectrod
integr
bottom
tissu
cultur
eplat
imped
measur
provid
quantit
inform
biolog
statu
cell
includ
cell
number
viabil
adher
cell
seed
densiti
cellswel
h
seed
cell
treat
differ
concentr
aurintricarboxyl
acid
benserazid
hydrochlorid
tannic
acid
hexachlorophen
prolifer
rate
cell
measur
addit
h
aoaa
use
posit
control
cb
inhibit
lactat
dehydrogenas
ldh
releas
cultur
medium
use
determin
cell
death
describ
briefli
supernat
collect
h
mix
freshli
prepar
ldh
assay
reagent
contain
mm
lactic
acid
mm
nicotinamid
adenin
dinucleotid
nad
mm
nmethylphenazonium
methyl
sulfat
pm
mm
chlorid
int
mm
tri
ph
chang
absorb
read
kinet
nm
min
kinet
ldh
assay
monochromatorbas
reader
powerwav
ht
biotek
h
treatment
cell
variou
test
compound
cell
incub
medium
contain
mgml
bromid
mtt
emd
bioscienc
san
diego
ca
h
co
atmospher
describ
convert
formazan
dye
dissolv
dmso
absorb
measur
nm
monochromatorbas
reader
powerwav
ht
biotek
extracellular
flux
analysi
analyz
seahors
bioscienc
billerica
use
measur
effect
benserazid
h
incub
bioenerget
function
cell
describ
previous
creat
transient
chamber
special
micropl
allow
ocr
oxygen
consumpt
rate
ecar
extracellular
acidif
rate
monitor
real
time
h
chang
oxygen
proton
concentr
perform
realtim
measur
via
specif
fluoresc
dye
incorpor
seahors
flux
pak
cartridg
four
key
paramet
mitochondri
function
basal
respir
atp
turnov
proton
leak
maxim
respir
assess
sequenti
use
oligomycin
atp
synthas
inhibitor
fccp
oxid
phosphoryl
uncoupl
rotenon
antimycin
complex
iii
inhibitor
differ
maxim
basal
respir
consid
respiratori
reserv
capac
capac
cell
gener
atp
via
oxid
phosphoryl
respons
increas
demand
energi
inject
oligomycin
subsequ
inhibit
oxid
phosphoryl
ecar
extracellular
acidif
rate
also
measur
index
glycolyt
capac
cell
benserazid
dock
theoret
predict
plp
adduct
cb
activ
site
use
combiglid
algorithm
schroding
inc
describ
algorithm
combin
accur
ligandreceptor
score
highli
effici
combinatori
dock
algorithm
corehop
technolog
design
focus
librari
identifi
new
scaffold
dock
perform
use
ifd
inducedfit
dock
protocol
implement
smallmolecul
drug
discoveri
suit
schroding
inc
smallmolecul
drug
discoveri
suit
ifd
algorithm
involv
use
glide
prime
modul
dock
refin
respect
enabl
model
structur
chang
protein
effect
ligand
bind
achiev
implement
improv
sampl
approach
specif
sidechain
backbon
atom
allow
rearrang
iter
cycl
dock
protein
refin
case
sidechain
trim
van
der
waal
atom
radii
scale
set
protein
dock
ligand
prior
calcul
two
plpbenserazid
deriv
prepar
term
correct
proton
state
tautomer
stereoisomer
use
ligprep
routin
schroding
inc
crystal
structur
human
cb
pdb
id
util
dock
calcul
protein
prepar
perform
correspond
routin
implement
maestro
schroding
inc
water
molecul
cb
crystallograph
structur
retain
accord
protprep
default
set
anim
studi
approv
iacuc
utmb
athym
male
femal
mice
week
n
inject
subcutan
either
right
left
dorsum
cell
describ
three
day
later
mice
random
two
group
inject
subcutan
sq
either
phosphat
buffer
salin
pb
n
benserazid
mgkgday
sq
n
per
day
durat
experi
benserazid
solut
made
fresh
daili
immedi
prior
treatment
anim
tumor
dimens
measur
daili
transcutan
use
calip
anim
weight
also
record
data
present
mean
sem
analyz
use
graphpad
prism
softwar
spss
statist
analys
includ
studentt
test
oneway
anova
follow
bonferroni
multipl
comparison
order
identifi
novel
inhibitor
cb
screen
clinic
use
drug
wellannot
pharmacolog
compound
composit
collect
commerci
avail
librari
small
custom
librari
assembl
known
plpdepend
enzym
inhibitor
compound
consist
ornithin
decarboxylas
inhibitor
dldifluoromethylornithin
thymidyl
synthas
dihydrofol
reductas
glycinamid
ribonucleotid
formyltransferas
inhibitor
pemetrex
gaba
transaminas
inhibitor
vigabatrin
gaba
transaminas
aromat
lamino
acid
decarboxylas
inhibitor
dopa
decarboxylas
inhibitor
carbidopa
tabl
compound
screen
concentr
compound
show
cb
inhibit
consid
potenti
hit
number
potenti
hit
vari
librari
divers
collect
like
lopac
yield
dozen
potenti
hit
specif
collect
eg
actitarg
p
librari
plpdepend
custom
collect
nt
yield
potenti
hit
compound
repres
multipl
librari
posit
identifi
potenti
hit
compound
multipl
time
indic
reliabl
screen
assay
individu
cb
activ
compound
test
vehicl
control
organ
librari
shown
fig
plpdepend
enzym
inhibitor
compound
also
retest
broader
concentrationrespons
rang
inhibitori
effect
observ
except
inhibit
cb
activ
respect
carbidopa
weak
inhibitor
cb
activ
inhibit
confirmatori
assay
perform
compound
repurchas
commerci
sourc
potent
inhibitor
cbsstimul
azmc
fluoresc
signal
shown
tabl
take
account
fact
compound
contain
electrophil
moieti
could
directli
react
h
well
quench
coumarin
fluoresc
potenti
hit
compound
counterscreen
h
donor
ident
reaction
condit
major
potenti
hit
compound
decreas
azmc
fluoresc
tabl
compound
could
confirm
cb
inhibitor
potenc
compar
aoaa
without
significantli
interf
azmc
fluoresc
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
four
compound
character
along
princip
refer
compound
aoaa
secondari
refer
compound
inhibitori
effect
two
refer
compound
four
identifi
cb
inhibitor
recombin
cb
azmc
fluoresc
shown
tabl
full
concentrationrespons
curv
shown
fig
structur
six
compound
two
refer
compound
four
compound
identifi
screen
bona
fide
cb
inhibitor
shown
fig
cb
inhibitori
effect
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
also
confirm
use
methylen
blue
assay
detect
h
product
differ
principl
azmc
assay
tabl
unexpectedli
second
refer
compound
cb
inhibitor
addit
inhibit
cbsinduc
azmc
fluoresc
ic
also
inhibit
azmc
fluoresc
ic
tabl
fig
indic
observ
inhibitori
effect
due
combin
direct
cb
inhibit
well
h
scaveng
andor
interfer
assay
use
detect
h
conduct
confirmatori
doserespons
work
four
compound
identifi
cb
inhibitor
note
aqueou
instabl
benserazid
freshli
made
solut
produc
inhibit
depict
storag
benserazid
stock
solut
aqueou
media
dmso
diminish
activ
instanc
freshli
dissolv
benserazid
inhibit
cb
activ
prepar
stock
solut
pb
dmso
store
week
potenc
decreas
inhibit
cb
activ
respect
n
data
consist
prior
find
show
oxidationpron
charact
benserazid
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
well
two
refer
compound
aoaa
fig
fig
next
test
cell
prolifer
human
colon
carcinoma
cell
line
cytotox
assess
parallel
ldh
releas
assay
mtt
assay
aoaa
concentrationdepend
inhibit
cell
prolifer
ic
valu
respect
fig
effect
also
associ
suppress
mtt
convers
fig
four
compound
identifi
cb
screen
hexachlorophen
least
potent
cb
inhibitor
among
four
identifi
hit
compound
affect
prolifer
fulli
inhibit
cell
prolifer
fig
howev
concentr
compound
also
exert
cytotox
effect
indic
increas
ldh
releas
fig
polyphenol
tannic
acid
concentrationdepend
inhibit
prolifer
start
complet
inhibit
seen
without
sign
cytotox
fig
aurintricarboxyl
acid
although
exhibit
vitro
cb
inhibitori
potenc
compar
aoaa
inhibit
cell
prolifer
increas
cell
prolifer
fig
although
benserazid
less
potent
inhibit
recombin
cb
aoaa
cellfre
assay
potent
aoaa
prolifer
assay
benserazid
inhibit
prolifer
cell
steep
doserespons
curv
concentr
exert
inhibitori
effect
wherea
benserazid
complet
inhibit
prolifer
increas
ldh
releas
fig
among
potent
potenti
hit
compound
identifi
tabl
sever
contain
copper
instanc
chlorophyllid
cu
complex
na
salt
contain
killer
plate
librari
natur
product
librari
respect
howev
copperfre
analogu
fail
inhibit
recombin
cb
activ
fig
suggest
copper
may
inhibitor
cb
activ
addit
inhibit
cbsinduc
azmc
fluoresc
also
inhibit
azmc
respons
although
lower
potenc
ic
vs
fig
followup
assay
test
effect
three
differ
cu
salt
druzhyna
activ
recombin
cbsinduc
azmc
fluoresc
well
azmc
fluoresc
shown
tabl
salt
copper
ii
chlorid
copper
ii
acet
copper
ii
nitrat
exhibit
potent
inhibitori
effect
recombin
cb
ic
lesser
degre
inhibitori
effect
also
note
azmc
respons
inhibit
ic
fact
effect
coppercontain
compound
effect
cucl
overlap
cbsand
azmc
fluoresc
valu
fig
investig
role
cb
inhibit
copper
perform
cell
prolifer
assay
cell
shown
fig
copper
inhibit
cell
prolifer
highest
concentr
test
mm
also
decreas
mtt
convers
ldh
activ
paradox
reduct
ldh
activ
like
result
previous
report
direct
inhibit
ldh
enzym
copper
ion
major
benserazid
metabolit
thbh
also
known
ro
also
act
cb
inhibitor
potenc
compar
benserazid
exert
inhibit
recombin
cb
activ
n
inhibit
cell
prolifer
vitro
reduc
mtt
convers
exert
cytotox
effect
evidenc
lack
signific
increas
ldh
concentr
cell
cultur
medium
fig
benserazid
contain
free
group
react
aldehyd
group
produc
schiff
base
gain
insight
put
mode
cb
inhibit
benserazid
dock
calcul
perform
consid
two
distinct
plpbenserazid
deriv
could
potenti
form
either
potenti
repres
actual
inhibitor
protein
fig
compound
fig
top
deriv
coupl
free
amin
unmodifi
benserazid
formyl
function
plp
compound
fig
bottom
deriv
obtain
reaction
major
benserazid
metabolit
respect
moieti
plp
molecul
expect
rel
kinet
stabl
result
schiff
base
carri
aromat
ring
substitut
compound
compound
dock
plpbind
site
cb
use
inducedfit
dock
protocol
enabl
addit
flexibl
enhanc
sampl
model
structur
rearrang
target
upon
bind
dock
result
show
although
molecul
adopt
highli
ident
geometri
respect
crystallograph
free
plp
cofactor
plpbenserazid
deriv
systemat
bound
demonstr
moder
higher
dock
score
correspond
plptrihydroxybenzylhydrazin
deriv
respect
differ
kcalmol
best
pose
score
kcalmol
kcal
mol
basi
higher
affin
predict
attribut
interact
geometri
permit
format
addit
hydrophob
contact
protein
environ
well
extens
hydrogen
bond
interact
trihydroxybenzyl
ring
polar
residu
locat
peripheri
caviti
respect
correspond
lessfavor
interact
geometri
fig
c
equilibrium
two
differ
state
benserazid
rule
assay
condit
dock
show
two
molecul
demonstr
high
structur
converg
term
bind
orient
cb
inhibitori
potenc
benserazid
depend
concentr
substrat
use
assay
mixtur
reduct
concentr
cystein
homocystein
mm
standard
assay
condit
mm
increas
inhibitori
potenc
benserazid
instanc
standard
assay
condit
benserazid
inhibit
cb
activ
low
substrat
condit
concentr
benserazid
exert
inhibitori
effect
n
hand
doubl
substrat
concentr
mm
reduc
inhibitori
potenc
benserazid
instanc
standard
assay
condit
benserazid
inhibit
cb
activ
high
substrat
condit
concentr
benserazid
exert
inhibitori
effect
n
benserazid
rel
select
cb
inhibitor
cse
activ
slightli
affect
inhibit
n
activ
unaffect
activ
presenc
benserazid
vehicl
control
n
benserazid
exert
inhibitori
effect
bioenerget
colon
cancer
cell
inhibit
oxid
phosphorylationmitochondri
electron
transport
fig
without
significantli
affect
glycolysi
fig
addit
cell
benserazid
also
inhibit
cell
line
prolifer
colon
cancer
cell
line
fig
cell
line
similar
cell
express
high
level
cb
lower
concentr
benserazid
also
exert
cytotox
effect
cell
fig
contrast
benserazid
inhibit
prolifer
anoth
colon
cancer
cell
line
lovo
fig
cell
line
lower
express
cb
express
high
level
cse
anoth
h
sproduc
enzym
final
benserazid
prevent
growth
subcutan
xenograft
tumorbear
nude
mice
vivo
fig
main
conclus
current
studi
follow
composit
librari
clinic
use
drug
wellannot
pharmacolog
compound
compound
identifi
cb
inhibitori
activ
nonspecif
scaveng
effect
interfer
assay
condit
compound
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
b
three
identifi
cb
inhibitor
also
exert
inhibitori
effect
cell
prolifer
unexpectedli
aurintricarboxyl
acid
fail
inhibit
cell
prolifer
fact
exert
stimulatori
effect
highest
concentr
test
c
benserazid
rel
select
cb
inhibitor
versu
cse
model
studi
predict
benserazid
manner
similar
mode
aoaa
action
interact
plp
prosthet
group
activ
site
cb
view
like
mode
cb
inhibit
e
benserazid
inhibit
colon
cancer
cell
prolifer
highcbsexpressor
cell
line
lovo
cell
express
lower
level
cb
f
benserazid
inhibit
cellular
bioenerget
cell
g
benserazid
suppress
colon
cancer
growth
tumorbear
mice
base
data
suggest
benserazid
explor
respect
potenti
suitabl
therapeut
repurpos
cancer
addit
data
present
current
report
confirm
previou
find
demonstr
copper
direct
inhibitor
cb
activ
final
confirm
refer
compound
aoaa
cb
inhibitor
antiprolif
agent
colon
cancer
cell
second
refer
compound
found
potent
inhibit
cbsinduc
azmc
fluoresc
respons
also
h
donor
azmc
fluoresc
suggest
least
part
inhibit
cbsinduc
signal
unrel
direct
inhibit
catalyt
activ
cb
nevertheless
found
potent
inhibitor
cell
prolifer
vitro
hexachlorophen
methyl
phenol
organochlorin
compound
wide
use
disinfect
common
use
skin
cleans
newborn
withdrawn
due
safeti
issu
hexachlorophen
known
sever
pharmacolog
activ
includ
inhibit
tar
dna
bind
protein
inhibit
coronaviru
entri
inhibit
amyloid
assembl
hexachlorophen
also
known
glutaminas
inhibitor
inhibitor
betacatenin
pathway
previous
identifi
cb
inhibitor
h
biosynthesi
inhibitor
even
though
alreadi
shown
inhibit
tumor
cell
prolifer
vitro
effect
attribut
inhibitori
effect
catenin
pathway
even
though
hexachlorophen
inhibit
prolifer
fairli
low
concentr
base
histori
toxicolog
profil
compound
believ
therapeut
repurpos
compound
cb
inhibitor
realist
option
common
natur
polyphenol
product
variou
plant
tara
pod
gallnut
sicilian
sumac
leav
tannic
acid
use
certain
food
industri
albumin
tannat
use
antidiarrh
agent
thorson
colleagu
previous
identifi
anoth
polyphenol
rutin
cb
inhibitor
knowledg
first
report
identifi
tannic
acid
cb
inhibitor
although
polyphenol
natur
tannic
acid
suggest
nonspecif
eg
potenti
h
scaveng
properti
variou
polyphenol
tannic
acid
interfer
azmc
respons
induc
h
donor
compound
interestingli
tannin
report
inhibit
bacteri
h
product
effect
hypothes
may
relat
inhibitori
effect
bacteri
h
sproduc
enzym
tannic
acid
exert
concentrationdepend
inhibitori
effect
cell
prolifer
ic
multipl
line
studi
previous
identifi
anticanc
effect
tannin
although
exact
mechan
clearli
elucid
rang
direct
cytotox
inhibit
variou
put
target
enzym
includ
proteasom
base
current
studi
hypothes
inhibit
tumor
cb
activ
may
contribut
anticanc
effect
tannin
next
cb
inhibitor
identifi
screen
aurintricarboxyl
acid
knowledg
previous
identifi
cb
inhibitor
compound
propens
polymer
aqueou
solut
form
stabl
free
radic
shown
inhibit
variou
proteinnucl
acid
interact
previous
shown
possess
number
pharmacolog
activ
includ
proteas
inhibit
complement
inhibit
ribonucleas
inhibit
neuraminidas
inhibit
also
shown
stimul
insulinlik
growth
factor
receptor
akt
erk
signal
stimul
cell
prolifer
aurintricarboxyl
acid
observ
experi
similar
previous
observ
stimul
cell
prolifer
variou
cell
line
compound
may
relat
abil
compound
stimul
variou
prolif
signal
pathway
hypothes
action
predomin
cell
antiprolif
effect
would
expect
via
cb
inhibit
although
mode
action
divers
pharmacolog
effect
suggest
lack
specif
perhap
lack
vivo
util
surprisingli
aurintricarboxyl
acid
toler
experiment
anim
fact
shown
produc
therapeut
benefit
varieti
condit
includ
enceph
sepsi
final
screen
followup
work
identifi
benserazid
rs
propanehydrazid
cb
inhibitor
ic
thorson
colleagu
previous
report
cb
inhibitori
effect
benserazid
albeit
lower
potenc
hypothes
differ
may
relat
aqueou
instabl
oxidationpron
natur
compound
demonstr
current
studi
well
report
previous
benserazid
produc
expect
featur
cb
inhibitor
similar
aoaa
shown
previous
benserazid
inhibit
colon
cancer
cell
prolifer
suppress
cancer
cell
bioenerget
respons
computerbas
model
studi
identifi
predict
mode
inhibitori
action
note
nevertheless
extent
benserazid
suppress
prolifer
colon
cancer
cell
depend
cell
type
studi
signific
suppress
prolifer
highest
concentr
test
degre
cytotox
evidenc
increas
ldh
releas
note
cell
fig
cell
fig
express
rel
high
concentr
cb
comparison
lovo
cell
express
lower
level
cb
neither
benserazideinduc
antiprolif
effect
benserazideinduc
increas
ldh
releas
seen
fig
data
support
conclus
benserazid
target
cb
howev
well
awar
fact
mani
possibl
may
explain
differenti
effect
includ
potenti
differ
cell
uptak
potenti
differ
cellular
metabol
benserazid
benserazid
one
compon
twocompon
oral
antiparkinson
therapeut
combin
compon
ldopa
origin
mode
benserazid
mode
action
inhibit
peripher
dopa
decarboxylas
similar
cb
plpdepend
enzym
enzym
case
benserazid
bind
plp
prosthet
group
target
necessarili
predict
tissu
level
degre
inhibit
intracellular
target
importantli
rat
studi
benserazid
concentr
kidney
liver
higher
plasma
concentr
h
singl
dose
administr
addit
benserazid
data
indic
major
metabolit
thbh
also
act
cb
inhibitor
colon
cancer
cell
antiprolif
agent
fig
base
pharmacokinet
consider
predict
tumor
tissu
concentr
compar
antiprolif
concentr
benserazid
well
metabolit
may
achiev
vivo
may
open
potenti
therapeut
repurpos
compound
one
way
predict
target
engag
survey
literatur
biochem
alter
potenti
biomark
benserazid
administr
may
suggest
cb
inhibit
found
publish
studi
literatur
effect
benserazid
h
product
h
level
therefor
focus
secondari
biomark
sinc
liver
cb
play
physiolog
role
plasma
homocystein
metabol
predict
cb
target
engag
benserazid
human
may
induc
hyperhomocysteinemia
inde
recent
studi
show
benserazid
parkinson
patient
produc
increas
plasma
homocystein
level
interpret
inactiv
cb
benserazid
follow
accumul
substrat
homocystein
circul
pharmacokinet
pharmacodynam
studi
need
determin
feasibl
benserazid
potenti
repurpos
agent
experiment
therapi
cancer
one
sidefind
current
work
rerediscoveri
inhibitori
effect
copper
ion
cb
activ
find
alreadi
describ
matsuo
greenberg
rediscov
krau
group
although
potenc
copper
found
remark
fact
copper
technic
potent
cb
inhibitor
compound
known
date
free
copper
ion
exert
antiprolif
effect
cell
probabl
due
limit
cell
uptak
well
high
abil
cell
sequest
neutral
free
copper
ion
futur
work
need
determin
whether
abil
copper
inhibit
cb
may
use
context
therapeut
cb
inhibit
anoth
side
find
current
project
discoveri
second
refer
cb
inhibitor
compound
potent
inhibit
cbsinduc
azmc
fluoresc
respons
also
h
donor
azmc
fluoresc
suggest
least
part
inhibit
cbsinduc
signal
unrel
direct
inhibit
catalyt
activ
cb
nevertheless
found
potent
inhibitor
cell
prolifer
amongst
molecul
evalu
current
project
given
fact
howev
compound
known
highli
potent
inhibitor
pathway
well
inhibitor
hypothes
inhibit
sirt
inhibit
significantli
contribut
potent
inhibitori
effect
cancer
cell
prolifer
vitro
work
need
dissect
variou
possibl
mechan
inhibit
sirt
inhibit
cb
inhibit
perhap
action
well
antiprolif
action
third
sidefind
current
studi
demonstr
none
known
plpdepend
enzym
inhibitor
exert
potent
inhibitori
effect
cb
prior
studi
demonstr
pag
plpdepend
inhibitor
cse
inhibitor
cb
similarli
dcycloserin
isoniazid
two
antibiot
suppress
tuberculosi
infect
via
inhibit
multipl
plpdepend
enzym
fail
act
signific
inhibitor
cb
activ
inhibit
mm
base
data
conclud
plpdepend
enzym
inhibit
suffici
criterion
cb
inhibit
taken
togeth
current
work
character
potenc
select
antiprolif
bioenerget
action
benserazid
one
cb
inhibitor
identifi
vitro
screen
base
find
report
current
articl
conclud
benserazid
may
potenti
suitabl
repurpos
treatment
colorect
cancer
although
pharmacokinet
pharmacodynam
preclin
anim
studi
necessari
structur
two
refer
compound
aoaa
four
compound
identifi
screen
bona
fide
cb
inhibitor
hexachlorophen
tannic
acid
aurintricarboxyl
acid
benserazid
effect
benserazid
cellular
bioenerget
cell
paramet
oxid
phosphoryl
b
glycolysi
shown
bioenerget
paramet
normal
protein
content
data
repres
mean
sem
n
determin
p
p
show
signific
differ
compar
vehicl
control
show
signific
differ
compar
vehicl
control
show
signific
differ
compar
vehicl
control
effect
benserazid
mgkgday
sq
growth
cell
xenograft
nude
mice
data
show
mean
sem
tumor
size
anim
weight
n
mice
per
group
p
show
signific
effect
benserazid
tumor
size
compar
vehicl
control
tabl
list
librari
use
current
screen
campaign
tabl
list
potenti
hit
compound
identifi
primari
screen
effect
compound
fluoresc
respons
compound
screen
except
compound
indic
asterisk
test
conduct
indic
concentr
cbsinduc
azmc
fluoresc
retest
except
compound
indic
asterisk
test
conduct
indic
concentr
cbsand
azmc
fluoresc
data
shown
mean
sem
n
